Sponsor Dossier
Roche Products
Sponsor Dossier for Roche Products. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACTEMRA
- Brand: ALECENSA
- Brand: CELLCEPT
- Brand: COLUMVI
- Brand: COTELLIC
- Brand: ENSPRYNG
- Brand: ERIVEDGE
- Brand: EVRYSDI
- Device (sponsor): Ophthalmic anaesthesia needle
- Device (sponsor): Ophthalmic implant handling forceps, single-use
- Device (sponsor): Ophthalmic anaesthesia needle
- Device (sponsor): Medication transfer set
- Device (sponsor): Self-care monitoring web-based application software
- Device (sponsor): Medication transfer set
- Device (sponsor): Medicine administration kit, percutaneous, non-medicated, single-use
- Device (sponsor): Contivue Implant with ITA (Insertion Tool Assembly - Implantable intraocular medication reservoir
About
Roche Products is an Australian Private Company with ABN 70000132865, registered in New South Wales with entity status Active.
Portfolio
Roche Products has 27 brands on the ARTG, with 26 indexable brands and 26 brands with Product Information on file. The portfolio includes 18 brands with at least one PBS-listed item, 18 brands with PBAC outcome(s) on record, and 13 brands with AusPAR(s) on record. Notable brands include ACTEMRA, ALECENSA, CELLCEPT, COLUMVI, COTELLIC, ENSPRYNG, ERIVEDGE, EVRYSDI, GAZYVA, HEMLIBRA, HERCEPTIN, and ITOVEBI.
Therapeutic focus —
Oncology: 15 brands — Neurology: 4 brands — Haematology: 2 brands — Immunology: 2 brands — Infectious Disease: 2 brands — Ophthalmology: 1 brand — Respiratory: 1 brand
PBS footprint
Eighteen brands in the Roche Products portfolio have at least one PBS-listed item, with the portfolio's latest PBS schedule date being 2026-05-01.
Regulatory activity
The latest PBAC outcome for Roche Products is dated 2025-07-01, with 18 brands holding PBAC outcomes on record. The latest AusPAR is dated 2025-03-24, with 13 brands holding AusPARs on record.